Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Phase I Dose Escalating Study of APR-246 for Infusion in Patients With Refractory Hematologic Malignancies or Prostate Carcinoma

NCT00900614 is registered in ClinicalTrials.gov with Aprea Therapeutics as lead sponsor.

NCT NCT00900614
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00900614 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Phase I Dose Escalating Study of APR-246 for Infusion in Patients With Refractory Hematologic Malignancies or Prostate Carcinoma
Lead sponsor
Aprea Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2009
Completion date
October 31, 2010
Enrollment
36 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

hematologic neoplasms, prostatic neoplasms